Although the serum MFAP4 risk model developed in the test cohort tended to underestimate the observed risk of advanced fibrosis and cirrhosis in the validation cohort, the overall difference between the predicted and the observed risk in the validation cohort did not differ significantly for either advanced fibrosis (Hosmer‐Lemeshow 14.86, P = .06) or cirrhosis (Hosmer‐Lemeshow 14.76, P = .06). This evidence concerns the gene MFAP4 and fibrosis.